New approaches for detecting complement-fixing antibodies

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 409-415

  Tyan, Dolly B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; C1q assay; C4d assay; Complement; Desensitization

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; COMPLEMENT FIXING ANTIBODY; EPITOPE; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; PANEL REACTIVE ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; CARDIAC GRAFT REJECTION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; COMPLEMENT FIXATION TEST; CORRELATIONAL STUDY; DESENSITIZATION; GLOMERULOPATHY; GOLD STANDARD; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HLA SYSTEM; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; PROGNOSIS; RENAL GRAFT DYSFUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIBODIES; COMPLEMENT C1Q; COMPLEMENT C4B; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; PEPTIDE FRAGMENTS;

EID: 84863847357     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328355fb9b     Document Type: Review

References (34)

1. Bradley JA, Baldwin WM, Bingaman A, et al. Antibody-mediated rejection-an ounce of prevention is worth a pound of cure. Am J Transplant 2011; 11:1131-1139.
2. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78:152-159.
3. Damman J, Seelen MA, Moers C, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 2011; 92:163-169.
4. Susal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive luminex single-antigen testing: a Collaborative Transplant Study Report. Transplantation 2011; 91:883-887.
5. Higgins R, Lowe D, Hathaway M, et al. Human leukocyte antigen antibodyincompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92:900-906.
6. Focosi D, Boggi U. Pretransplant screening for donor-specific antibodies and graft loss. Transplantation 2011; 92:E15.
7. Susal C, Opelz G. Pretransplant screening for donor-specific antibodies and graft loss reply. Transplantation 2011; 92:E15-E16.
8. Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 2011; 91:527-535.
9. Patel R, Terasaki PI. Significance of positive crossmatch test in kidney transplantation. New Engl J Med 1969; 280:735-739.
10. Wahrmann M, Exner M, Regele H, et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003; 275:149-160.
11. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies: a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7:2809-2815.
12. Heeger PS. A complementary approach to treating antibody-mediated transplant rejection. Kidney Int 2010; 78:125-127.
13. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72:849-858.
14. Chen G, Sequeira F, Tyan D. Parallel C1q and IgG assays on single antigen beads reveal that the presence of IgM complement fixing antibodies can obscure clinically relevant IgG antibodies to the same allele. Hum Immunol 2011; 72:S12.
15. Rhodes CL, Mata N, Abes P, Rao P. Detection of C1q-fixing antibodies correlates with AHG-complement dependent cytotoxicity crossmatch results. Hum Immunol 2011; 72:S58.
16. Lunz JG, Webber S, Soltys K, et al. C1q binding donor specific HLA antibody monitoring by Luminex single antigen assay is useful in predicting clinical events. Hum Immunol 2011; 72:S50.
17. Chen G, Sequeira F, Tyan D. Luminex-C1q: a reliable virtual crossmatch (VXM) to predict final CDC crossmatch. Hum Immunol 2011; 72:S14.
18. Fuller A, Williams K, Hurst D, et al. HLA antibodies that are not detected by the C1q screen (can fix complement and are clinically significant. Hum Immunol 2011; 72:S30.
19. Phelan DL, Harrell K, Clark D, Mohanakumar T. Which Is the clinically relevant antibody in patients waiting for transplantation: Luminex SAB screens versus C1q assays? Hum Immunol 2011; 72:S54.
20. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant. 2012; 12:1618-1623.
21. Kukuruga D, Drachenberg C, Haririan A. Association of C4d staining, single antigen antibody analysis and the C1q binding assay. Hum Immunol 2011; 72:S13.
22. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beads: a technical solution for the prozone effect. Transplantation 2011; 92:510-515.
23. Page S, Fuggle S, Vaidya A, Friend P. C1q-fixing antibodies in highly sensitised patients waiting for a small bowel transplant without the liver. The Oxford experience. X11 International Small Bowel Transplant Symposium, Washington DC, Abstract Book www.isbts2011.org. [Accessed on 15-18 November 2011].
24. Honger G, Hopfer H, Arnold ML, et al. Pretransplant IgG subclasses of donorspecific human leukocyte antigen antibodies and development of antibodymediated rejection. Transplantation 2011; 92:41-47.
25. Wahrmann M, Exner M, Schillinger M, et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6 (5 Pt 1):1033-1041.
26. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: Associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8:41-49.
27. Honger G, Wahrmann M, Amico P, et al. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89:1471-1475.
28. Mizutani K, Gotoh M. C4d binding correlated with strong HLA antibodies involved in graft failures. Transplant Proc 2010; 42:4021-4025.
29. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11:312-319.
30. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91:342-347.
31. Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donorspecific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16:12-17.
32. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulinGantibodies capable of fixing complement in sensitized pediatric heart transplant patients. JHeart Lung Transplant2011; 30: 158-163.
33. Zeevi A, Marrari M, Feingold B, et al. Human leukocyte antigen epitope analysis to assess complement-and noncomplement-binding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol 2012; 73:48-51.
34. Tyan D, Yabu J, Chen G, et al. Successful avoidance of posttransplant antibody mediated rejection when desensitizing patients with IVIG: in vitro C1q test predicts and monitors in vivo efficacy and time to transplant. Am J Transplant 2011; 11 (S2):91.